Want to see ENSC full AI Analyst Report?
Top Page
Ensysce Biosciences
(NASDAQ:ENSC)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.35
▲(35.38% Upside)
Action:Reiterated
Date:08/26/26
The score is held down primarily by weak financial performance (large ongoing losses, persistent cash burn, and negative equity). Technicals are neutral-to-mixed with oversold readings but a clear longer-term downtrend versus the 200-day average. Corporate events add some upside via financing and pipeline expansion, but are tempered by meaningful Nasdaq listing/compliance overhangs.
Positive Factors
Abuse-deterrent platform
The TAAP and MPAR platforms address persistent opioid-safety needs by combining analgesia with barriers to tampering and high-dose misuse, potentially supporting differentiated products and partnerships if clinical development succeeds.
Negative Factors
Persistent large losses
Losses remain many times larger than reported revenue, showing that development and corporate costs substantially exceed current commercial activity and leaving limited evidence of operating leverage or near-term self-sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Abuse-deterrent platform
The TAAP and MPAR platforms address persistent opioid-safety needs by combining analgesia with barriers to tampering and high-dose misuse, potentially supporting differentiated products and partnerships if clinical development succeeds.
Read all positive factors
Ensysce Biosciences (ENSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.02M
Dividend YieldN/A
Average Volume (3M)89.63K
Price to Earnings (P/E)―
Beta (1Y)2.18
Revenue Growth-39.29%
EPS Growth27.41%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,456,795
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ensysce Biosciences Business Overview & Revenue Model
Company Description
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and over...
How the Company Makes Money
null...
Ensysce Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.61M | -10.15M | -6.70M | -10.27M | -24.10M | -27.85M |
| Net Income | -12.62M | -10.18M | -7.99M | -10.61M | -24.17M | -29.08M |
Balance Sheet | ||||||
| Total Assets | 2.96M | 7.45M | 5.60M | 2.71M | 5.89M | 16.42M |
| Cash, Cash Equivalents and Short-Term Investments | 676.70K | 4.31M | 3.50M | 1.12M | 3.15M | 12.26M |
| Total Debt | 196.84K | 306.71K | 301.66K | 854.70K | 4.43M | 17.21M |
| Total Liabilities | 4.07M | 4.57M | 2.22M | 3.36M | 9.91M | 24.58M |
| Stockholders Equity | -781.70K | 3.21M | 3.71M | -322.86K | -3.71M | -7.88M |
Cash Flow | ||||||
| Free Cash Flow | -8.98M | -7.93M | -7.50M | -10.78M | -17.89M | -8.24M |
| Operating Cash Flow | -8.86M | -7.81M | -7.50M | -10.78M | -17.89M | -8.24M |
| Investing Cash Flow | -123.64K | -123.64K | 0.00 | 0.00 | 4.50K | 0.00 |
| Financing Cash Flow | 7.44M | 8.74M | 9.88M | 8.76M | 8.77M | 20.31M |
Ensysce Biosciences Technical Analysis
Positive
0.26
Price Trends
0.32
Positive
0.34
Positive
0.65
Negative
Market Momentum
0.02
Positive
56.02
Neutral
58.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENSC, the sentiment is Positive. The current price of 0.26 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.32, and below the 200-day MA of 0.65, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 56.02 is Neutral, neither overbought nor oversold. The STOCH value of 58.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENSC.
Ensysce Biosciences Risk Analysis
Ensysce Biosciences disclosed 48 risk factors in its most recent earnings report. Ensysce Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ensysce Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
ENSC
Ensysce Biosciences
0.40
-1.70
-81.00%
GLMD
Galmed Pharmaceuticals
4.31
-6.73
-61.01%
CYCN
Cyclerion Therapeutics
3.99
1.42
55.25%
SILO
Silo Pharma
2.54
-7.05
-73.50%
ALZN
Alzamend Neuro
1.67
-0.77
-31.48%
Ensysce Biosciences Corporate Events
Delistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles
Negative
Aug 25, 2026
On May 21, 2026, Ensysce Biosciences disclosed that Nasdaq had warned the company over non-compliance with the $2.5 million stockholders’ equity requirement as of March 31, 2026, triggering a potential delisting process unless a remediation ...
Delistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period
Positive
Aug 24, 2026
On August 5, 2026, Ensysce Biosciences acquired Cy Biopharma, Inc. and entered into a Securities Purchase Agreement to issue 120,260 shares of Series C Preferred Stock for approximately $43 million in financing, structured in two tranches. At the ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio
Positive
Aug 6, 2026
On August 5, 2026, Ensysce Biosciences completed the stock-for-stock acquisition of Cy Biopharma, making Cy a wholly owned subsidiary and shifting majority ownership of the combined company to Cy’s former equityholders once Series C preferre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.